Drug or treatment
Evolocumab clinical trials
As of November 12, 2026, Find a Trial lists 5 clinical trials of Evolocumab that are recruiting, at sites in 3 countries (most in China (3), Switzerland (1), United States (1)). By phase: Phase 4 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 3Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Early LDL-C lowering with evolocumab after ACS to see if it slows plaque progression | Phase 4 | Xi’an, Shanxi and 1 other locations | Recruiting | May 29, 2026 |
| Long-term use of inclisiran, evolocumab, and alirocumab in real-world care | — | Basel | Recruiting | Apr 22, 2026 |
| Adding evolocumab to usual lipid-lowering care for acute pancreatitis caused by very high triglycerides | — | Shenyang, Liaoning | Recruiting | Feb 5, 2026 |
| Intelligent lipid-management system to help stroke or TIA patients on evolocumab reach one-year LDL-C targets | — | Beijing | Recruiting | Aug 27, 2025 |
| Evaluating the effects of obicetrapib and evolocumab on Lp(a) levels | Phase 2 | Philadelphia, Pennsylvania | Recruiting | Jul 11, 2024 |
All recruiting trials (5)
-
Early LDL-C lowering with evolocumab after ACS to see if it slows plaque progression
This trial tests whether starting evolocumab soon after a heart attack or unstable angina, in addition to standard therapy, reduces non-culprit plaque growth over a year.
-
Long-term use of inclisiran, evolocumab, and alirocumab in real-world care
This study tests whether people with high cholesterol medications stick with their PCSK9 inhibitors and inclisiran over the long term in everyday clinical practice.
-
Adding evolocumab to usual lipid-lowering care for acute pancreatitis caused by very high triglycerides
This study will try adding evolocumab to standard lipid-lowering care for adults hospitalized with hypertriglyceridemia-induced acute pancreatitis to see if it lowers triglycerides faster and reaches target levels within a week.
-
Intelligent lipid-management system to help stroke or TIA patients on evolocumab reach one-year LDL-C targets
We will test whether an intelligent lipid-management decision-support system helps adults in China with ischemic stroke or TIA who are taking evolocumab reach LDL-C under 1.8 mmol/L after one year.
-
Evaluating the effects of obicetrapib and evolocumab on Lp(a) levels
This study is testing if a new medication called obicetrapib, alone and with another drug called evolocumab, can lower Lp(a) levels in people who have high Lp(a).
Quick answers
How many clinical trials of Evolocumab are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in China (3 trials), Switzerland (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 4: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.